These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31679427)

  • 21. Prevalence of Hypertension, Treatment, and Blood Pressure Targets in Canada Associated With the 2017 American College of Cardiology and American Heart Association Blood Pressure Guidelines.
    Garies S; Hao S; McBrien K; Williamson T; Peng M; Khan NA; Padwal RS; Quan H; Leung AA;
    JAMA Netw Open; 2019 Mar; 2(3):e190406. PubMed ID: 30848811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current Trends in Hypertension Identification and Management: Insights from the National Health and Nutrition Examination Survey (NHANES) Following the 2017 ACC/AHA High Blood Pressure Guidelines.
    Heaton J; Alshami A; Imburgio S; Mararenko A; Schoenfeld M; Sealove B; Asif A; Almendral J
    J Am Heart Assoc; 2024 Apr; 13(8):e034322. PubMed ID: 38563377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diastolic Hypotension May Attenuate Benefits from Intensive Systolic Targets: Secondary Analysis of a Randomized Controlled Trial.
    Lee TC; Cavalcanti RB; McDonald EG; Pilote L; Brophy JM
    Am J Med; 2018 Oct; 131(10):1228-1233.e1. PubMed ID: 29906425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Lowering Diastolic Pressure in Patients With and Without Cardiovascular Disease: Analysis of the SPRINT (Systolic Blood Pressure Intervention Trial).
    Khan NA; Rabkin SW; Zhao Y; McAlister FA; Park JE; Guan M; Chan S; Humphries KH
    Hypertension; 2018 May; 71(5):840-847. PubMed ID: 29581214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. More Versus Less Intensive Blood Pressure-Lowering Strategy: Cumulative Evidence and Trial Sequential Analysis.
    Verdecchia P; Angeli F; Gentile G; Reboldi G
    Hypertension; 2016 Sep; 68(3):642-53. PubMed ID: 27456518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefits and Harms of Antihypertensive Treatment in Low-Risk Patients With Mild Hypertension.
    Sheppard JP; Stevens S; Stevens R; Martin U; Mant J; Hobbs FDR; McManus RJ
    JAMA Intern Med; 2018 Dec; 178(12):1626-1634. PubMed ID: 30383082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial.
    Byrne C; Pareek M; Vaduganathan M; Biering-Sørensen T; Qamar A; Pandey A; Olesen TB; Olsen MH; Bhatt DL
    Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):356-363. PubMed ID: 31529024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort.
    Kavousi M; Leening MJ; Nanchen D; Greenland P; Graham IM; Steyerberg EW; Ikram MA; Stricker BH; Hofman A; Franco OH
    JAMA; 2014 Apr; 311(14):1416-23. PubMed ID: 24681960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baseline Blood Pressure, the 2017 ACC/AHA High Blood Pressure Guidelines, and Long-Term Cardiovascular Risk in SPRINT.
    Vaduganathan M; Pareek M; Qamar A; Pandey A; Olsen MH; Bhatt DL
    Am J Med; 2018 Aug; 131(8):956-960. PubMed ID: 29421687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimated Population Health Benefits of Intensive Systolic Blood Pressure Treatment Among SPRINT-Eligible US Adults.
    Derington CG; Bress AP; Berchie RO; Herrick JS; Shen J; Ying J; Greene T; Tajeu GS; Sakhuja S; Ruiz-Negrón N; Zhang Y; Howard G; Levitan EB; Muntner P; Safford MM; Whelton PK; Weintraub WS; Moran AE; Bellows BK
    Am J Hypertens; 2023 Aug; 36(9):498-508. PubMed ID: 37378472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 13 - benefits and adverse events in older and younger patients with hypertension: overview, meta-analyses and meta-regression analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2018 Aug; 36(8):1622-1636. PubMed ID: 29847485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of new hypertension guidelines in the United States.
    Bertoia ML; Waring ME; Gupta PS; Roberts MB; Eaton CB
    Hypertension; 2012 Sep; 60(3):639-44. PubMed ID: 22868391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Reboussin DM; Allen NB; Griswold ME; Guallar E; Hong Y; Lackland DT; Miller EPR; Polonsky T; Thompson-Paul AM; Vupputuri S
    Hypertension; 2018 Jun; 71(6):e116-e135. PubMed ID: 29133355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serious Adverse Events Cluster in Participants Experiencing the Primary Composite Cardiovascular Endpoint: A Post Hoc Analysis of the SPRINT Trial.
    Botchway A; Buhnerkempe MG; Prakash V; Al-Akchar M; Adekola B; Flack JM
    Am J Hypertens; 2020 May; 33(6):528-533. PubMed ID: 31930338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management plans for populations with normal-to-hypertensive blood pressures: risks and benefits of antihypertensive drug treatment in populations previously defined as having high-normal blood pressure.
    Park S
    Korean J Intern Med; 2019 Jan; 34(1):44-49. PubMed ID: 30612417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systolic Blood Pressure Intervention Trial (SPRINT) and Target Systolic Blood Pressure in Future Hypertension Guidelines.
    Egan BM; Li J; Wagner CS
    Hypertension; 2016 Aug; 68(2):318-23. PubMed ID: 27354422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Body Mass Index, Intensive Blood Pressure Management, and Cardiovascular Events in the SPRINT Trial.
    Oxlund CS; Pareek M; Rasmussen BSB; Vaduganathan M; Biering-Sørensen T; Byrne C; Almarzooq Z; Olsen MH; Bhatt DL
    Am J Med; 2019 Jul; 132(7):840-846. PubMed ID: 30721655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Personalized prediction of adverse heart and kidney events using baseline and longitudinal data from SPRINT and ACCORD.
    Dinstag G; Amar D; Ingelsson E; Ashley E; Shamir R
    PLoS One; 2019; 14(8):e0219728. PubMed ID: 31393900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.
    Rosendorff C; Lackland DT; Allison M; Aronow WS; Black HR; Blumenthal RS; Cannon CP; de Lemos JA; Elliott WJ; Findeiss L; Gersh BJ; Gore JM; Levy D; Long JB; O'Connor CM; O'Gara PT; Ogedegbe G; Oparil S; White WB;
    Hypertension; 2015 Jun; 65(6):1372-407. PubMed ID: 25828847
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.